Albumin-based drug carrier targeting urokinase receptor for cancer therapy.

[1]  B. Ghosh,et al.  Human serum albumin-poly(Lactide)-conjugated self-assembly NPs for targeted docetaxel delivery and improved therapeutic efficacy in oral cancer. , 2022, International journal of biological macromolecules.

[2]  C. Yuan,et al.  A versatile insertion point on albumin to accommodate peptides and maintain their activities. , 2022, International journal of biological macromolecules.

[3]  B. Ghosh,et al.  Oleanolic Acid-conjugated human serum albumin nanoparticles encapsulating doxorubicin as synergistic combination chemotherapy in oropharyngeal carcinoma and melanoma. , 2022, International journal of pharmaceutics.

[4]  M. Ploug,et al.  The Urokinase Receptor (uPAR) as a “Trojan Horse” in Targeted Cancer Therapy: Challenges and Opportunities , 2021, Cancers.

[5]  Y. Zhen,et al.  The development of human serum albumin-based drugs and relevant fusion proteins for cancer therapy. , 2021, International journal of biological macromolecules.

[6]  Jakob Nikolas Kather,et al.  Serum Levels of Soluble Urokinase Plasminogen Activator Receptor Predict Tumor Response and Outcome to Immune Checkpoint Inhibitor Therapy , 2021, Frontiers in Oncology.

[7]  C. Yuan,et al.  Development of inhibitors for uPAR: blocking the interaction of uPAR with its partners. , 2021, Drug discovery today.

[8]  M. Otagiri,et al.  Serum Albumin, Lipid and Drug Binding. , 2020, Sub-cellular biochemistry.

[9]  Wei Gao,et al.  Correction to: Celastrol mediates autophagy and apoptosis via the ROS/JNK and Akt/mTOR signaling pathways in glioma cells , 2019, Journal of experimental & clinical cancer research : CR.

[10]  G. Rabbani,et al.  Structure, enzymatic activities, glycation and therapeutic potential of human serum albumin: A natural cargo. , 2019, International journal of biological macromolecules.

[11]  Chern Ein Oon,et al.  Molecular targeted therapy: Treating cancer with specificity , 2018, European journal of pharmacology.

[12]  J. Zhao,et al.  A Mechanistic Overview of Triptolide and Celastrol, Natural Products from Tripterygium wilfordii Hook F , 2018, Front. Pharmacol..

[13]  O. Abdallah,et al.  Self-assembled phospholipid-based phytosomal nanocarriers as promising platforms for improving oral bioavailability of the anticancer celastrol. , 2018, International journal of pharmaceutics.

[14]  Chen Jiang,et al.  Biomacromolecules as carriers in drug delivery and tissue engineering , 2017, Acta pharmaceutica Sinica. B.

[15]  J. Fonseca,et al.  Celastrol: A Spectrum of Treatment Opportunities in Chronic Diseases , 2017, Front. Med..

[16]  X. Miao,et al.  Celastrol inhibits chondrosarcoma proliferation, migration and invasion through suppression CIP2A/c-MYC signaling pathway. , 2017, Journal of pharmacological sciences.

[17]  C. H. Nielsen,et al.  First-in-human uPAR PET: Imaging of Cancer Aggressiveness , 2015, Theranostics.

[18]  C. Yuan,et al.  A drug carrier targeting murine uPAR for photodynamic therapy and tumor imaging. , 2015, Acta biomaterialia.

[19]  W. Strohl.  Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters , 2015, BioDrugs.

[20]  Yunmei Huang,et al.  Zinc phthalocyanine conjugated with the amino-terminal fragment of urokinase for tumor-targeting photodynamic therapy. , 2014, Acta biomaterialia.

[21]  Xiaole Qi,et al.  Solid self-microemulsifying dispersible tablets of celastrol: formulation development, charaterization and bioavailability evaluation. , 2014, International journal of pharmaceutics.

[22]  S. Lippard,et al.  Pt(IV) Prodrugs Designed to Bind Non-Covalently to Human Serum Albumin for Drug Delivery , 2014, Journal of the American Chemical Society.

[23]  H. Nielsen,et al.  Urokinase-type plasminogen activator receptor (uPAR) on tumor-associated macrophages is a marker of poor prognosis in colorectal cancer , 2014, Cancer medicine.

[24]  Guang-Biao Zhou,et al.  Cancerous inhibitor of PP2A is targeted by natural compound celastrol for degradation in non-small-cell lung cancer. , 2014, Carcinogenesis.

[25]  Wei Zheng,et al.  A Novel Tumor Targeting Drug Carrier for Optical Imaging and Therapy , 2014, Theranostics.

[26]  Yaping Wang,et al.  Comparative Study of Somatostatin-Human Serum Albumin Fusion Proteins and Natural Somatostatin on Receptor Binding, Internalization and Activation , 2014, PloS one.

[27]  Leslie R Evans,et al.  Albumin as a versatile platform for drug half-life extension. , 2013, Biochimica et biophysica acta.

[28]  Sang Mee Lee,et al.  Novel AGLP-1 albumin fusion protein as a long-lasting agent for type 2 diabetes , 2013, BMB reports.

[29]  Shuang Huang,et al.  Role of Urokinase Receptor in Tumor Progression and Development , 2013, Theranostics.

[30]  A. Kjaer,et al.  Urokinase-type plasminogen activator receptor (uPAR) as a promising new imaging target: potential clinical applications , 2013, Clinical physiology and functional imaging.

[31]  Mingdong Huang,et al.  Structure-based Engineering of Species Selectivity in the Interaction between Urokinase and Its Receptor , 2010, The Journal of Biological Chemistry.

[32]  C. Marshall,et al.  Regulation of cell signalling by uPAR , 2010, Nature Reviews Molecular Cell Biology.

[33]  Paula D. Bos,et al.  Metastasis: from dissemination to organ-specific colonization , 2009, Nature Reviews Cancer.

[34]  Mingdong Huang,et al.  A new drug binding subsite on human serum albumin and drug-drug interaction studied by X-ray crystallography. , 2008, Journal of structural biology.

[35]  Craig M. Crews,et al.  Molecular Understanding and Modern Application of Traditional Medicines: Triumphs and Trials , 2007, Cell.

[36]  Patrick Soon-Shiong,et al.  Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  S. Curry,et al.  Structural basis of the drug-binding specificity of human serum albumin. , 2005, Journal of molecular biology.

[38]  A. Ménez,et al.  Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide , 2005, The EMBO journal.

[39]  C. D. de Bock,et al.  Clinical significance of urokinase‐type plasminogen activator receptor (uPAR) expression in cancer , 2004, Medicinal research reviews.

[40]  N. Schmiedeberg,et al.  Synthesis, solution structure, and biological evaluation of urokinase type plasminogen activator (uPA)-derived receptor binding domain mimetics. , 2002, Journal of medicinal chemistry.

[41]  W. Hall,et al.  Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT. , 2002, Journal of the National Cancer Institute.

[42]  M. Ploug,et al.  Peptide-derived antagonists of the urokinase receptor. affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation. , 2001, Biochemistry.

[43]  S. Curry,et al.  Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin. , 2000, Journal of molecular biology.

[44]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.